Nuvalent (NUVL) Change in Acquisitions & Divestments (2022 - 2026)
Nuvalent's (NUVL) quarterly Change in Acquisitions & Divestments came in at $181.5 million in Q1 2026, down 40.0% YoY from $302.6 million in Q1 2025, and up 11.31% on a QoQ basis from $163.1 million in Q4 2025.
Nuvalent (NUVL) Change in Acquisitions & Divestments (2022 - 2026) Analysis & Trends
Nuvalent (NUVL) has 5 years of Change in Acquisitions & Divestments data on file, last reported at $181.5 million in Q1 2026.
- Quarterly Change in Acquisitions & Divestments fell 40.0% year-over-year to $181.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $812.6 million (up 19.9% YoY) and the FY2025 annual result came in at $933.7 million, up 106.82% from the prior year.
- Change in Acquisitions & Divestments grew to $181.5 million in Q1 2026, from $163.1 million in the prior quarter.
- In the past five years, Change in Acquisitions & Divestments ranged from a high of $302.6 million in Q1 2025 to a low of $27.0 million in Q1 2022.
- A 5-year average of $122.6 million and a median of $105.0 million in 2024 frame the typical range for Change in Acquisitions & Divestments.
- Annual changes were most pronounced in 2025 — Change in Acquisitions & Divestments soared 296.85% — and 2026, when it slumped 40.0%.
- Tracing NUVL's Change in Acquisitions & Divestments over 5 years: stood at $97.2 million in 2022, then climbed by 13.62% to $110.5 million in 2023, then increased by 28.96% to $142.4 million in 2024, then increased by 14.5% to $163.1 million in 2025, then rose by 11.31% to $181.5 million in 2026.
- The last three Change in Acquisitions & Divestments figures came in at $181.5 million (Q1 2026), $163.1 million (Q4 2025), and $232.4 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Nuvalent | 9.10 Bn | 9.10 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 181.55 Mn |
| Mar 31, 2026 | 181.55 Mn |
| Dec 31, 2025 | 163.10 Mn |
| Dec 31, 2025 | 163.10 Mn |
| Sep 30, 2025 | 232.44 Mn |
| Sep 30, 2025 | 232.44 Mn |
| Jun 30, 2025 | 235.55 Mn |
| Jun 30, 2025 | 235.55 Mn |
| Mar 31, 2025 | 302.59 Mn |
| Mar 31, 2025 | 302.59 Mn |
| Dec 31, 2024 | 142.45 Mn |
| Dec 31, 2024 | 142.45 Mn |
| Sep 30, 2024 | 127.71 Mn |
| Sep 30, 2024 | 127.71 Mn |
| Jun 30, 2024 | 105.04 Mn |
| Jun 30, 2024 | 105.04 Mn |
| Mar 31, 2024 | 76.25 Mn |
| Mar 31, 2024 | 76.25 Mn |
| Dec 31, 2023 | 110.46 Mn |
| Dec 31, 2023 | 110.46 Mn |